German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher energy costs and the effect. | March 29, 2023
Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® R&D investments of 5 billion EUR, or 21 percent of net sales Net sales rise 10.5 percent (currency adjusted)
• Boehringer Ingelheim is one of 15 global Top Employers worldwide • Outstanding employer benefits with emphasis on wellbeing, attractive work environment, and rewards and recognition The Top Employers
Since entering a multi-project target discovery collaboration in January 2020, when PhoreMost deployed its phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways selected by Boehringer Ingelheim, PhoreMost has triggered a milestone payment, achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies to transform patients’ lives. Click to read more.
Boehringer Ingelheim is strengthening its commitment to positively impact people, animals, communities and the planet through key sustainability initiatives in the Philippines and across ASEAN, South Korea, Australia, and New Zealand (ASKAN).